Finding 512282 (2023-002)

Material Weakness
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-11-26
Audit: 330028
Organization: Center on Halsted (IL)
Auditor: Rsm US LLP

AI Summary

  • Core Issue: Financial and performance reports were submitted late, violating grant agreement timelines.
  • Impacted Requirements: Non-compliance with Articles XIII and XIV of the grant agreements regarding timely reporting.
  • Recommended Follow-Up: Establish a verification process to ensure all reports are submitted on time and retain proper documentation for each submission.

Finding Text

Finding 2023-002: Reporting—financial and performance reports Assistance Listing Number title and number: COVID-19- Coronavirus State and Local Fiscal Recovery Funds, 21.027 Federal grant number: FSCAH06318 Federal agency: U.S. Department of Treasury Pass through entity: Illinois Department of Human Services, Cook County Health and Illinois Criminal Justice Information Authority Criteria: Article XIII 13.1 and 13.2 of the Coronavirus State and Local Fiscal Recovery Funds – American Rescue Plan Act Add on and Article XIV 14.1 and 14.2 of the Illinois Criminal Justice Information Authority – American Rescue Plan Act grant agreements state that financial and performance reports are to be submitted within 15 days after quarter-end for quarterly reports, 15 days after month-end for monthly reports, and 30 days after grant agreement close period. Condition: Certain financial and performance reports were filed late. Cause: Due to turnover in both financial management and program management, program oversight was not performed timely. Effect: The Center is not in compliance with Article XIII 13.1 and 13.2, and Article XIV 14.1 and 14.2 of the grant agreements. Questioned costs: None Context: Out of 21 financial and performance monthly reports tested, 16 of the financial and performance reports were filed late. Repeat finding: No Recommendation: We recommend that management implement a process to verify that all reports are reviewed and submitted within the required timelines set by the funding agency. We also recommend management retain proper support for each report submitted. Views of responsible officials: Management agrees with this finding. Please see corrective action plan attached.

Categories

Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 512254 2023-001
    Material Weakness
  • 512255 2023-002
    Material Weakness
  • 512256 2023-003
    Significant Deficiency
  • 512257 2023-003
    Significant Deficiency
  • 512258 2023-003
    Significant Deficiency
  • 512259 2023-003
    Significant Deficiency
  • 512260 2023-003
    Significant Deficiency
  • 512261 2023-003
    Significant Deficiency
  • 512262 2023-003
    Significant Deficiency
  • 512263 2023-003
    Significant Deficiency
  • 512264 2023-003
    Significant Deficiency
  • 512265 2023-003
    Significant Deficiency
  • 512266 2023-003
    Significant Deficiency
  • 512267 2023-003
    Significant Deficiency
  • 512268 2023-003
    Significant Deficiency
  • 512269 2023-003
    Significant Deficiency
  • 512270 2023-003
    Significant Deficiency
  • 512271 2023-003
    Significant Deficiency
  • 512272 2023-003
    Significant Deficiency
  • 512273 2023-003
    Significant Deficiency
  • 512274 2023-003
    Significant Deficiency
  • 512275 2023-003
    Significant Deficiency
  • 512276 2023-003
    Significant Deficiency
  • 512277 2023-003
    Significant Deficiency
  • 512278 2023-003
    Significant Deficiency
  • 512279 2023-001
    Material Weakness
  • 512280 2023-002
    Material Weakness
  • 512281 2023-001
    Material Weakness
  • 1088696 2023-001
    Material Weakness
  • 1088697 2023-002
    Material Weakness
  • 1088698 2023-003
    Significant Deficiency
  • 1088699 2023-003
    Significant Deficiency
  • 1088700 2023-003
    Significant Deficiency
  • 1088701 2023-003
    Significant Deficiency
  • 1088702 2023-003
    Significant Deficiency
  • 1088703 2023-003
    Significant Deficiency
  • 1088704 2023-003
    Significant Deficiency
  • 1088705 2023-003
    Significant Deficiency
  • 1088706 2023-003
    Significant Deficiency
  • 1088707 2023-003
    Significant Deficiency
  • 1088708 2023-003
    Significant Deficiency
  • 1088709 2023-003
    Significant Deficiency
  • 1088710 2023-003
    Significant Deficiency
  • 1088711 2023-003
    Significant Deficiency
  • 1088712 2023-003
    Significant Deficiency
  • 1088713 2023-003
    Significant Deficiency
  • 1088714 2023-003
    Significant Deficiency
  • 1088715 2023-003
    Significant Deficiency
  • 1088716 2023-003
    Significant Deficiency
  • 1088717 2023-003
    Significant Deficiency
  • 1088718 2023-003
    Significant Deficiency
  • 1088719 2023-003
    Significant Deficiency
  • 1088720 2023-003
    Significant Deficiency
  • 1088721 2023-001
    Material Weakness
  • 1088722 2023-002
    Material Weakness
  • 1088723 2023-001
    Material Weakness
  • 1088724 2023-002
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
21.027 Covid-19-Coronavirus State and Local Fiscal Recovery Funds $163,350
14.241 Housing Opportunities for Persons with Aids $93,139
93.940 Hiv Prevention Activities_health Department Based $74,270
93.914 Hiv Emergency Relief Project Grants $46,183
16.034 Covid-19-Coronavirus Emergency Supplemental Funding Program $33,115
93.368 21st Century Cures Act - Precision Medicine Initiative $22,612
16.575 Crime Victim Assistance $22,015
97.008 Non-Profit Security Program $242